XTalks
NOVEMBER 1, 2024
TIME Magazine’s “ Best Inventions of 2024 ” list highlights impressive breakthroughs across sectors, including a variety of inventive solutions in the food industry. Last year’s food inventions spotlighted unique products like a sugar pen, an advanced avocado variety and a cutting-edge induction cooktop, proving that innovation in food is diverse and expansive.
Bio Pharma Dive
NOVEMBER 1, 2024
The Phase 3 findings position semaglutide to become the first drug of its kind for the liver disease. But they also confirm GLP-1s aren't a "silver bullet" for MASH, one analyst argued.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
NOVEMBER 1, 2024
Verastem Oncology has concluded the rolling submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for a combination of avutometinib and defactinib for low-grade serous ovarian cancer (LGSOC).
Bio Pharma Dive
NOVEMBER 1, 2024
Regeneron shares continued to decline on growing concerns about Eylea’s future. Elsewhere, new details emerged about Lundbeck’s Longboard buyout and PTC continued a quixotic quest.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
NOVEMBER 1, 2024
The US District Court upholds the FDA’s approval of Avadel’s Lumryz, dismissing Jazz’s challenge over market exclusivity for its own drug.
Fierce Pharma
NOVEMBER 1, 2024
With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing up to pursue yet another indication for its star GLP-1 medicine semagluti | Novo Nordisk on Friday revealed that its star GLP-1 semaglutide met the mark in a late-stage MASH study. The positive results build on the thesis that GLP-1s could become a foundational piece in the treatment paradigm for the fatty liver disease, according to analysts at William Blair.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Fierce Pharma
NOVEMBER 1, 2024
An FDA announcement last year of an investigation into the risk of patients developing secondary cancers following the treatment of CAR-T cell therapies sent shock waves across the industry. | An FDA investigation last year into the risk of patients developing secondary cancers following the treatment of CAR-T cell therapies sent shock waves across the industry.
Pharmaceutical Technology
NOVEMBER 1, 2024
AbbVie has entered into a partnership and option-to-license agreement with EvolveImmune Therapeutics, to develop next-generation cancer biotherapeutics.
pharmaphorum
NOVEMBER 1, 2024
With artificial intelligence technologies for healthcare on the rise, UK health technology assessment (HTA) agency NICE has published an economic evaluation standard that it says will help inform coverage and reimbursement decisions.
Pharmaceutical Technology
NOVEMBER 1, 2024
The committee was not convinced that the benefit of Zynquista outweighed the risk in adults with type 1 diabetes and chronic kidney disease.
Fierce Pharma
NOVEMBER 1, 2024
Despite its unique ability to block sodium-glucose linked transporter 2 (SGLT2) in the kidneys and SGLT1 in the intestines, Lexicon’s Zynquista (sotagliflozin) has had difficulty negotiating r | Despite its unique ability to block sodium-glucose linked transporter 2 (SGLT2) in the kidneys and SGLT1 in the intestines, Lexicon’s Zynquista (sotagliflozin) has had difficulty negotiating regulatory hurdles.
Pharmaceutical Technology
NOVEMBER 1, 2024
Decentralized clinical trials are transforming medical research with more flexibility, improved patient engagement and faster recruitment.
pharmaphorum
NOVEMBER 1, 2024
FDA advisors vote against Lexicon Pharma's type 1 diabetes and chronic kidney disease therapy sotagliflozin ahead of December verdict
Pharmaceutical Technology
NOVEMBER 1, 2024
Through a partnership, the NCCN is adapting its Harmonized Guidelines for cancer treatment for use in Vietnam.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Fierce Pharma
NOVEMBER 1, 2024
Just a few months into a new launch in chronic inflammatory demyelinating polyneuropathy (CIDP), agrenx’ Vyvgart is already making headway in the rare disease space, just one of the long-term growt | So far, argenx's Vyvgart has reached 300 patients with chronic inflammatory demyelinating polyneuropathy (CIDP) after securing an FDA approval in the disease in late June.
BioPharma Reporter
NOVEMBER 1, 2024
A new case study released by AllazoHealth reveals that a leading rare disease pharmaceutical company achieved a 10.4% increase in therapy initiation, driven by AI-enabled patient outreach and personalized communications.
Pharmaceutical Commerce
NOVEMBER 1, 2024
Analysis finds that while basic Part D coverage costs have decreased by 4%, mid- and high-tier plans have seen hikes of 4% and 21%, respectively.
BioPharma Reporter
NOVEMBER 1, 2024
At CPHI Milan 2024, Abzena showcased its latest innovations in cell line development and ADC manufacturing, featuring the advanced AbZelectPRO platform and ThioBridge linker technology.
Drug Channels
NOVEMBER 1, 2024
Today’s guest post comes from Kimberley Chiang, Vice President of Biopharma Commercial Solutions at CoverMyMeds Kimberley highlghts the crucial roles of field reimbursement managers in removing access and reimbursement barriers. She then identifies the keys to successful implementation of field reimbursement services. To learn more, register for CoverMyMeds' November 13, 2024, webinar: Specialty Therapies & Field Reimbursement Services: Driving Better Outcomes for Brands and Patients.
XTalks
NOVEMBER 1, 2024
The neurology drug market continues to be dynamic with novel treatments that cater to a broad range of neurological and psychiatric conditions. In 2024, several blockbuster neurology medications are set to lead the market, capturing the attention of healthcare professionals, investors and patients alike. This year, key players like Roche, AbbVie and Janssen have bolstered their offerings with therapies targeting multiple sclerosis (MS), migraines, schizophrenia and more, each leveraging unique m
Fierce Pharma
NOVEMBER 1, 2024
After prior settlements, Apotex and Heritage hand over a combined $49M to resolve longstanding price-fixing claims fkansteiner Fri, 11/01/2024 - 10:19
pharmaphorum
NOVEMBER 1, 2024
Eisai and Biogen complete their rolling application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Pharma Marketing Network
NOVEMBER 1, 2024
The world of pharma marketing is changing rapidly, and 2025 will be no exception. For pharma marketing executives, adapting to these shifts isn’t just about keeping up—it’s about staying ahead. From digital transformation and personalized marketing to compliance and competition, the upcoming years will demand flexibility and innovative thinking. So, what will be the top challenges in 2025, and how can pharma marketers tackle them?
pharmaphorum
NOVEMBER 1, 2024
The 8th Antigen-Specific Immune Tolerance Drug Development Summit is an event organised by Hanson Wade. Discover the latest developments and networking opportunities at this leading industry conference.
Pharma Marketing Network
NOVEMBER 1, 2024
Pharmaceutical marketing moves fast. In an industry where new technologies, regulations, and consumer expectations are constantly shifting, staying informed is critical for marketing success. For pharma marketing executives, tracking news isn’t just about staying updated—it’s about staying competitive. This guide will outline effective ways to stay on top of pharmaceutical marketing news, so you’re always ready to make informed, timely decisions.
pharmaphorum
NOVEMBER 1, 2024
Join the 8th CAR-TCR Summit Europe hosted by Hanson Wade, your go-to European hub for the latest innovations in next-generation cell therapy. Discover how this event can propel your knowledge and expertise.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Commerce
NOVEMBER 1, 2024
In the first part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Delphine Perridy, chief commercial officer, Envirotainer, describes the progression of expectations when it comes to the sector, specifically as it relates to new drug development.
pharmaphorum
NOVEMBER 1, 2024
Join the Proteomic Based Drug Discovery Summit 2025 to stay updated on the latest trends in drug development and network with industry experts. Visit our website to register and be part of this exciting event.
Drug Discovery World podcast
NOVEMBER 1, 2024
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with Owen Smith, Partner at 4BIO Capital. Owen began his investment career at life science venture capital, working with early-stage biotechnology companies.
pharmaphorum
NOVEMBER 1, 2024
Experience the latest in tumor models research at the 9th Tumor Models San Francisco Summit in 2025. Stay updated on cutting-edge developments and network with leading researchers in the field.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Expert insights. Personalized for you.
95 
Let's personalize your content